| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| West Nile Fever | 47 | 2023 | 139 | 13.740 |
Why?
|
| West Nile virus | 36 | 2023 | 117 | 10.020 |
Why?
|
| Chagas Disease | 24 | 2024 | 292 | 6.930 |
Why?
|
| Trypanosoma cruzi | 17 | 2024 | 234 | 4.520 |
Why?
|
| Insect Vectors | 19 | 2024 | 109 | 4.360 |
Why?
|
| Triatoma | 10 | 2024 | 29 | 3.800 |
Why?
|
| Texas | 49 | 2023 | 3580 | 2.360 |
Why?
|
| RNA, Viral | 7 | 2024 | 540 | 2.270 |
Why?
|
| Communicable Diseases, Emerging | 7 | 2018 | 63 | 2.200 |
Why?
|
| Dengue | 6 | 2024 | 113 | 1.650 |
Why?
|
| Disease Outbreaks | 10 | 2020 | 320 | 1.650 |
Why?
|
| Dengue Virus | 3 | 2024 | 127 | 1.400 |
Why?
|
| Body Fluids | 3 | 2019 | 47 | 1.390 |
Why?
|
| Zika Virus Infection | 5 | 2019 | 170 | 1.360 |
Why?
|
| Culicidae | 7 | 2021 | 67 | 1.260 |
Why?
|
| Antibodies, Viral | 11 | 2024 | 1151 | 1.210 |
Why?
|
| Renal Insufficiency, Chronic | 7 | 2022 | 727 | 1.190 |
Why?
|
| Animals, Wild | 5 | 2023 | 26 | 1.190 |
Why?
|
| Travel | 6 | 2024 | 116 | 1.150 |
Why?
|
| Humans | 118 | 2025 | 124005 | 1.090 |
Why?
|
| Cyclonic Storms | 3 | 2021 | 74 | 1.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2020 | 840 | 1.060 |
Why?
|
| Animals | 51 | 2024 | 33994 | 1.060 |
Why?
|
| Middle Aged | 45 | 2024 | 26569 | 0.970 |
Why?
|
| Nephritis, Interstitial | 4 | 2022 | 38 | 0.950 |
Why?
|
| Male | 71 | 2024 | 60908 | 0.950 |
Why?
|
| Zika Virus | 4 | 2019 | 143 | 0.930 |
Why?
|
| Disasters | 2 | 2020 | 100 | 0.930 |
Why?
|
| Encephalitis | 2 | 2020 | 109 | 0.920 |
Why?
|
| Sanitation | 1 | 2024 | 15 | 0.900 |
Why?
|
| Acute Kidney Injury | 4 | 2020 | 633 | 0.900 |
Why?
|
| Hygiene | 1 | 2024 | 25 | 0.900 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 2 | 2024 | 30 | 0.890 |
Why?
|
| Female | 69 | 2024 | 66186 | 0.880 |
Why?
|
| Zoonoses | 4 | 2015 | 43 | 0.870 |
Why?
|
| Mephitidae | 1 | 2023 | 2 | 0.840 |
Why?
|
| Arbovirus Infections | 3 | 2018 | 31 | 0.840 |
Why?
|
| Schools | 2 | 2024 | 218 | 0.830 |
Why?
|
| Adult | 45 | 2024 | 29292 | 0.830 |
Why?
|
| Polymerase Chain Reaction | 5 | 2019 | 1585 | 0.830 |
Why?
|
| Agricultural Workers' Diseases | 3 | 2020 | 14 | 0.820 |
Why?
|
| Aged | 35 | 2024 | 19516 | 0.800 |
Why?
|
| Young Adult | 28 | 2024 | 8971 | 0.800 |
Why?
|
| Cognition | 2 | 2018 | 707 | 0.790 |
Why?
|
| Immunoglobulin M | 5 | 2024 | 211 | 0.790 |
Why?
|
| Nervous System Diseases | 2 | 2016 | 373 | 0.750 |
Why?
|
| Aged, 80 and over | 20 | 2019 | 6461 | 0.740 |
Why?
|
| Adolescent | 30 | 2024 | 19222 | 0.720 |
Why?
|
| Nickel | 1 | 2020 | 22 | 0.710 |
Why?
|
| Trace Elements | 1 | 2020 | 24 | 0.710 |
Why?
|
| Prevalence | 9 | 2023 | 2441 | 0.710 |
Why?
|
| Risk Factors | 22 | 2020 | 10239 | 0.700 |
Why?
|
| Arboviruses | 2 | 2017 | 27 | 0.700 |
Why?
|
| Antibodies, Bacterial | 3 | 2018 | 388 | 0.690 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2019 | 1282 | 0.690 |
Why?
|
| Neglected Diseases | 2 | 2021 | 151 | 0.690 |
Why?
|
| Blood Donors | 3 | 2014 | 62 | 0.690 |
Why?
|
| Hashimoto Disease | 1 | 2020 | 21 | 0.680 |
Why?
|
| Cat-Scratch Disease | 1 | 2020 | 33 | 0.670 |
Why?
|
| Epidemiological Monitoring | 5 | 2018 | 59 | 0.670 |
Why?
|
| Earthquakes | 1 | 2019 | 5 | 0.670 |
Why?
|
| Rickettsia typhi | 2 | 2017 | 12 | 0.650 |
Why?
|
| Nicaragua | 6 | 2024 | 26 | 0.640 |
Why?
|
| Vagina | 2 | 2019 | 194 | 0.620 |
Why?
|
| Pandemics | 8 | 2024 | 1093 | 0.620 |
Why?
|
| Child | 32 | 2024 | 24327 | 0.620 |
Why?
|
| Spotted Fever Group Rickettsiosis | 1 | 2018 | 5 | 0.610 |
Why?
|
| Rickettsia | 1 | 2018 | 13 | 0.610 |
Why?
|
| Rabies | 2 | 2013 | 11 | 0.610 |
Why?
|
| Dog Diseases | 2 | 2009 | 49 | 0.610 |
Why?
|
| Occupational Exposure | 2 | 2020 | 127 | 0.600 |
Why?
|
| Individuality | 1 | 2018 | 34 | 0.600 |
Why?
|
| Endemic Diseases | 2 | 2020 | 55 | 0.590 |
Why?
|
| Alphavirus Infections | 1 | 2017 | 10 | 0.570 |
Why?
|
| Alphavirus | 1 | 2017 | 17 | 0.570 |
Why?
|
| Typhus, Endemic Flea-Borne | 1 | 2017 | 20 | 0.570 |
Why?
|
| Belize | 4 | 2025 | 13 | 0.560 |
Why?
|
| Population Surveillance | 5 | 2017 | 388 | 0.560 |
Why?
|
| United States | 18 | 2022 | 10853 | 0.560 |
Why?
|
| Rickettsia Infections | 1 | 2017 | 7 | 0.560 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2019 | 216 | 0.550 |
Why?
|
| Electromyography | 1 | 2017 | 162 | 0.540 |
Why?
|
| Neuromuscular Diseases | 1 | 2017 | 55 | 0.530 |
Why?
|
| Public Health | 3 | 2020 | 261 | 0.530 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 492 | 0.530 |
Why?
|
| Host-Parasite Interactions | 1 | 2016 | 69 | 0.530 |
Why?
|
| Food Chain | 1 | 2016 | 10 | 0.520 |
Why?
|
| Meningitis, Viral | 2 | 2016 | 10 | 0.520 |
Why?
|
| Cytokines | 5 | 2023 | 1285 | 0.510 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 473 | 0.510 |
Why?
|
| Longitudinal Studies | 6 | 2018 | 1317 | 0.510 |
Why?
|
| Child, Preschool | 19 | 2024 | 13978 | 0.510 |
Why?
|
| Rabies Vaccines | 2 | 2009 | 11 | 0.500 |
Why?
|
| Cohort Studies | 10 | 2020 | 4768 | 0.500 |
Why?
|
| Residence Characteristics | 2 | 2021 | 276 | 0.480 |
Why?
|
| Encephalitis, Viral | 1 | 2015 | 20 | 0.480 |
Why?
|
| Birds | 2 | 2015 | 85 | 0.480 |
Why?
|
| Hand Hygiene | 2 | 2025 | 13 | 0.470 |
Why?
|
| Saliva | 3 | 2019 | 114 | 0.430 |
Why?
|
| Global Health | 3 | 2016 | 558 | 0.430 |
Why?
|
| Retinal Diseases | 1 | 2016 | 172 | 0.430 |
Why?
|
| Communicable Diseases | 3 | 2022 | 160 | 0.420 |
Why?
|
| Fatigue | 1 | 2014 | 187 | 0.420 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1349 | 0.420 |
Why?
|
| Interferon Type I | 2 | 2023 | 107 | 0.410 |
Why?
|
| Disease Reservoirs | 3 | 2018 | 35 | 0.410 |
Why?
|
| Seasons | 6 | 2017 | 310 | 0.400 |
Why?
|
| Dogs | 4 | 2017 | 768 | 0.400 |
Why?
|
| Time Factors | 8 | 2019 | 6278 | 0.400 |
Why?
|
| Mexico | 3 | 2018 | 180 | 0.400 |
Why?
|
| Lakes | 1 | 2012 | 3 | 0.390 |
Why?
|
| Cross-Sectional Studies | 8 | 2023 | 3413 | 0.390 |
Why?
|
| Rivers | 1 | 2012 | 9 | 0.390 |
Why?
|
| Depression | 2 | 2012 | 1212 | 0.370 |
Why?
|
| Education, Graduate | 1 | 2011 | 20 | 0.370 |
Why?
|
| Students, Public Health | 1 | 2010 | 4 | 0.360 |
Why?
|
| West Nile Virus Vaccines | 2 | 2011 | 19 | 0.360 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2010 | 19 | 0.350 |
Why?
|
| Disaster Planning | 1 | 2011 | 63 | 0.350 |
Why?
|
| Infant | 14 | 2024 | 12437 | 0.350 |
Why?
|
| Animals, Domestic | 3 | 2016 | 31 | 0.350 |
Why?
|
| Vero Cells | 3 | 2023 | 110 | 0.350 |
Why?
|
| Cat Diseases | 1 | 2009 | 14 | 0.330 |
Why?
|
| Immunity, Innate | 3 | 2018 | 372 | 0.330 |
Why?
|
| History, 21st Century | 4 | 2019 | 266 | 0.330 |
Why?
|
| Water Supply | 2 | 2024 | 25 | 0.320 |
Why?
|
| Philippines | 3 | 2020 | 23 | 0.320 |
Why?
|
| Child Health | 2 | 2022 | 53 | 0.320 |
Why?
|
| Communicable Disease Control | 1 | 2010 | 130 | 0.320 |
Why?
|
| Retrospective Studies | 12 | 2024 | 16239 | 0.310 |
Why?
|
| Refugees | 1 | 2009 | 30 | 0.310 |
Why?
|
| Logistic Models | 5 | 2020 | 1799 | 0.310 |
Why?
|
| Semen | 2 | 2019 | 72 | 0.310 |
Why?
|
| Spine | 1 | 2009 | 143 | 0.310 |
Why?
|
| Phylogeny | 3 | 2022 | 696 | 0.310 |
Why?
|
| Quality of Life | 1 | 2018 | 1898 | 0.300 |
Why?
|
| Mass Screening | 1 | 2014 | 781 | 0.300 |
Why?
|
| Chikungunya Fever | 3 | 2018 | 27 | 0.300 |
Why?
|
| Seroepidemiologic Studies | 4 | 2018 | 121 | 0.290 |
Why?
|
| Opossums | 2 | 2017 | 12 | 0.290 |
Why?
|
| Case-Control Studies | 5 | 2020 | 3264 | 0.290 |
Why?
|
| Surgical Wound Infection | 1 | 2009 | 259 | 0.270 |
Why?
|
| Risk Assessment | 6 | 2018 | 3426 | 0.270 |
Why?
|
| Encephalomyelitis | 1 | 2006 | 4 | 0.270 |
Why?
|
| Virus Diseases | 2 | 2022 | 280 | 0.270 |
Why?
|
| Horse Diseases | 1 | 2006 | 32 | 0.260 |
Why?
|
| Surveys and Questionnaires | 5 | 2020 | 3681 | 0.260 |
Why?
|
| Incidence | 8 | 2021 | 3134 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2022 | 1369 | 0.260 |
Why?
|
| Epidemics | 2 | 2017 | 54 | 0.250 |
Why?
|
| Glomerular Filtration Rate | 3 | 2020 | 502 | 0.250 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2018 | 195 | 0.250 |
Why?
|
| Fever | 4 | 2023 | 293 | 0.250 |
Why?
|
| Adaptive Immunity | 2 | 2018 | 88 | 0.250 |
Why?
|
| Age Factors | 4 | 2019 | 2805 | 0.250 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2024 | 190 | 0.240 |
Why?
|
| Alcohols | 1 | 2025 | 18 | 0.240 |
Why?
|
| Hand Disinfection | 1 | 2025 | 15 | 0.240 |
Why?
|
| Insect Bites and Stings | 2 | 2015 | 38 | 0.240 |
Why?
|
| Kidney | 3 | 2017 | 1352 | 0.240 |
Why?
|
| Proteome | 2 | 2023 | 243 | 0.230 |
Why?
|
| Aging | 4 | 2020 | 1166 | 0.230 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 865 | 0.230 |
Why?
|
| Health Facilities | 1 | 2025 | 59 | 0.230 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2025 | 70 | 0.230 |
Why?
|
| Cats | 2 | 2017 | 117 | 0.220 |
Why?
|
| Vaccination | 1 | 2009 | 953 | 0.220 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 1421 | 0.220 |
Why?
|
| Serogroup | 1 | 2024 | 58 | 0.220 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 532 | 0.220 |
Why?
|
| Infant, Newborn | 6 | 2020 | 8170 | 0.220 |
Why?
|
| Oximetry | 1 | 2024 | 162 | 0.210 |
Why?
|
| Survival Analysis | 2 | 2019 | 1490 | 0.210 |
Why?
|
| Antibodies, Neutralizing | 4 | 2023 | 467 | 0.200 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2015 | 178 | 0.200 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2018 | 449 | 0.200 |
Why?
|
| Disease Susceptibility | 2 | 2014 | 296 | 0.200 |
Why?
|
| Hypoxia | 1 | 2024 | 249 | 0.200 |
Why?
|
| Substance P | 1 | 2022 | 34 | 0.200 |
Why?
|
| Haplotypes | 2 | 2022 | 514 | 0.200 |
Why?
|
| Lyme Disease | 1 | 2022 | 35 | 0.200 |
Why?
|
| Public Health Surveillance | 2 | 2019 | 37 | 0.200 |
Why?
|
| Guideline Adherence | 1 | 2025 | 380 | 0.200 |
Why?
|
| Work Performance | 1 | 2022 | 14 | 0.190 |
Why?
|
| Ehrlichiosis | 1 | 2021 | 10 | 0.190 |
Why?
|
| Respiratory Tract Infections | 1 | 2024 | 270 | 0.190 |
Why?
|
| Introduced Species | 1 | 2021 | 22 | 0.190 |
Why?
|
| Floods | 1 | 2021 | 14 | 0.180 |
Why?
|
| Tropical Medicine | 2 | 2020 | 104 | 0.180 |
Why?
|
| Cost of Illness | 3 | 2020 | 245 | 0.180 |
Why?
|
| Antigenic Variation | 1 | 2021 | 39 | 0.180 |
Why?
|
| Autoantibodies | 2 | 2023 | 434 | 0.180 |
Why?
|
| Farmers | 1 | 2020 | 12 | 0.180 |
Why?
|
| Nails | 1 | 2020 | 17 | 0.180 |
Why?
|
| Appendicitis | 1 | 2022 | 125 | 0.180 |
Why?
|
| Triatominae | 2 | 2017 | 4 | 0.180 |
Why?
|
| Microscopy, Electron | 2 | 2017 | 393 | 0.170 |
Why?
|
| Review Literature as Topic | 1 | 2020 | 44 | 0.170 |
Why?
|
| Health Personnel | 1 | 2025 | 503 | 0.170 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 156 | 0.170 |
Why?
|
| Renal Insufficiency | 1 | 2022 | 235 | 0.170 |
Why?
|
| Sentinel Surveillance | 3 | 2008 | 19 | 0.160 |
Why?
|
| Hospitalization | 1 | 2008 | 1768 | 0.160 |
Why?
|
| Immunization, Secondary | 1 | 2000 | 103 | 0.160 |
Why?
|
| Electroencephalography | 1 | 2024 | 864 | 0.160 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 171 | 0.160 |
Why?
|
| Biomarkers | 4 | 2018 | 3046 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 76 | 0.160 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 86 | 0.160 |
Why?
|
| Tick-Borne Diseases | 1 | 2018 | 10 | 0.160 |
Why?
|
| Creatinine | 1 | 2020 | 388 | 0.160 |
Why?
|
| Emergency Medicine | 1 | 2020 | 155 | 0.160 |
Why?
|
| Tuberculin Test | 1 | 2019 | 125 | 0.150 |
Why?
|
| Canada | 2 | 2020 | 300 | 0.150 |
Why?
|
| Deer | 1 | 2018 | 19 | 0.150 |
Why?
|
| Tropical Climate | 2 | 2015 | 49 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 393 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 5126 | 0.150 |
Why?
|
| Prognosis | 5 | 2018 | 4605 | 0.150 |
Why?
|
| Influenza, Human | 2 | 2015 | 658 | 0.150 |
Why?
|
| Mosquito Vectors | 1 | 2018 | 35 | 0.150 |
Why?
|
| Viral Vaccines | 1 | 2021 | 333 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2021 | 385 | 0.150 |
Why?
|
| Mice | 7 | 2023 | 17578 | 0.150 |
Why?
|
| History, 20th Century | 2 | 2019 | 381 | 0.150 |
Why?
|
| Haiti | 1 | 2017 | 11 | 0.140 |
Why?
|
| Relapsing Fever | 1 | 2018 | 56 | 0.140 |
Why?
|
| Tattooing | 1 | 2017 | 6 | 0.140 |
Why?
|
| Poliomyelitis | 1 | 2017 | 17 | 0.140 |
Why?
|
| Ctenocephalides | 1 | 2017 | 1 | 0.140 |
Why?
|
| Borrelia | 1 | 2018 | 68 | 0.140 |
Why?
|
| Rural Population | 2 | 2017 | 257 | 0.140 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2017 | 39 | 0.140 |
Why?
|
| Age of Onset | 1 | 2019 | 585 | 0.140 |
Why?
|
| DNA, Kinetoplast | 1 | 2017 | 3 | 0.140 |
Why?
|
| Neural Conduction | 1 | 2017 | 92 | 0.140 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2017 | 19 | 0.140 |
Why?
|
| Honduras | 1 | 2017 | 26 | 0.140 |
Why?
|
| Coyotes | 1 | 2016 | 3 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 3 | 2022 | 4387 | 0.140 |
Why?
|
| Culture Media, Conditioned | 1 | 2017 | 80 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2021 | 6113 | 0.140 |
Why?
|
| Neurologic Examination | 1 | 2017 | 194 | 0.140 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 1082 | 0.130 |
Why?
|
| Cause of Death | 1 | 2019 | 472 | 0.130 |
Why?
|
| Immunosenescence | 1 | 2016 | 3 | 0.130 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2017 | 48 | 0.130 |
Why?
|
| Growth Disorders | 1 | 2018 | 209 | 0.130 |
Why?
|
| Housing | 1 | 2016 | 59 | 0.130 |
Why?
|
| Disability Evaluation | 1 | 2017 | 188 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 1031 | 0.130 |
Why?
|
| Milk, Human | 1 | 2019 | 299 | 0.130 |
Why?
|
| Superantigens | 1 | 2015 | 20 | 0.130 |
Why?
|
| Saccharum | 1 | 2015 | 7 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 141 | 0.120 |
Why?
|
| Sigmodontinae | 1 | 2015 | 44 | 0.120 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 117 | 0.120 |
Why?
|
| Antigens, Protozoan | 1 | 2015 | 65 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2021 | 515 | 0.120 |
Why?
|
| Caribbean Region | 1 | 2015 | 19 | 0.120 |
Why?
|
| Parasitic Diseases | 1 | 2016 | 61 | 0.120 |
Why?
|
| Mammals | 1 | 2016 | 256 | 0.120 |
Why?
|
| Immunologic Memory | 1 | 2016 | 187 | 0.120 |
Why?
|
| Immunity, Humoral | 2 | 2015 | 69 | 0.120 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 323 | 0.120 |
Why?
|
| Human Activities | 1 | 2014 | 4 | 0.120 |
Why?
|
| Animal Distribution | 1 | 2014 | 10 | 0.120 |
Why?
|
| Leishmania guyanensis | 1 | 2014 | 3 | 0.120 |
Why?
|
| Tuberculosis | 1 | 2020 | 517 | 0.110 |
Why?
|
| Species Specificity | 1 | 2015 | 549 | 0.110 |
Why?
|
| Systems Biology | 1 | 2014 | 56 | 0.110 |
Why?
|
| Recreation | 1 | 2014 | 19 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 918 | 0.110 |
Why?
|
| Encephalitis, St. Louis | 1 | 2014 | 20 | 0.110 |
Why?
|
| Antibodies, Protozoan | 1 | 2014 | 75 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 2049 | 0.110 |
Why?
|
| Central Nervous System Infections | 1 | 2014 | 21 | 0.110 |
Why?
|
| Demography | 1 | 2015 | 238 | 0.110 |
Why?
|
| Disease Transmission, Infectious | 1 | 2015 | 84 | 0.110 |
Why?
|
| Brain | 2 | 2023 | 2977 | 0.110 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2014 | 47 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 381 | 0.110 |
Why?
|
| Pregnancy | 4 | 2019 | 7158 | 0.110 |
Why?
|
| Genotype | 1 | 2019 | 2552 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 1746 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2017 | 551 | 0.100 |
Why?
|
| Culex | 1 | 2013 | 33 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 382 | 0.100 |
Why?
|
| Prenatal Diagnosis | 1 | 2017 | 594 | 0.100 |
Why?
|
| Lipocalin-2 | 1 | 2012 | 29 | 0.100 |
Why?
|
| Lipocalins | 1 | 2012 | 30 | 0.100 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 47 | 0.100 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 143 | 0.100 |
Why?
|
| Phenotype | 2 | 2019 | 4242 | 0.100 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 121 | 0.100 |
Why?
|
| Pediatrics | 1 | 2020 | 1157 | 0.090 |
Why?
|
| Immunophenotyping | 3 | 2017 | 329 | 0.090 |
Why?
|
| Surge Capacity | 1 | 2010 | 8 | 0.090 |
Why?
|
| Poverty | 1 | 2014 | 417 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 775 | 0.090 |
Why?
|
| Rats | 1 | 2017 | 3675 | 0.090 |
Why?
|
| Feeding Behavior | 1 | 2016 | 711 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 2879 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 4333 | 0.080 |
Why?
|
| Aedes | 1 | 2011 | 100 | 0.080 |
Why?
|
| Povidone | 1 | 2009 | 5 | 0.080 |
Why?
|
| Faculty, Medical | 2 | 2023 | 262 | 0.080 |
Why?
|
| Iodine | 1 | 2009 | 23 | 0.080 |
Why?
|
| New Orleans | 1 | 2009 | 13 | 0.080 |
Why?
|
| Hospitals, Community | 1 | 2009 | 54 | 0.080 |
Why?
|
| Disease Progression | 2 | 2018 | 2045 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 801 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 544 | 0.080 |
Why?
|
| HIV Infections | 1 | 2020 | 1888 | 0.080 |
Why?
|
| Rickettsia prowazekii | 1 | 2008 | 1 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 1879 | 0.080 |
Why?
|
| Bird Diseases | 1 | 2008 | 9 | 0.080 |
Why?
|
| Acyclovir | 1 | 2008 | 45 | 0.070 |
Why?
|
| Safety Management | 1 | 2009 | 112 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 810 | 0.070 |
Why?
|
| Marijuana Smoking | 1 | 2007 | 31 | 0.070 |
Why?
|
| Mosquito Control | 1 | 2007 | 31 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2009 | 294 | 0.070 |
Why?
|
| Costs and Cost Analysis | 2 | 2014 | 164 | 0.070 |
Why?
|
| Horses | 1 | 2006 | 91 | 0.070 |
Why?
|
| Syndrome | 1 | 2009 | 1116 | 0.070 |
Why?
|
| Geography | 1 | 2006 | 110 | 0.070 |
Why?
|
| Gastroenteritis | 1 | 2009 | 348 | 0.060 |
Why?
|
| Curriculum | 1 | 2011 | 724 | 0.060 |
Why?
|
| Urban Population | 1 | 2007 | 225 | 0.060 |
Why?
|
| Hand Sanitizers | 1 | 2025 | 3 | 0.060 |
Why?
|
| Antibody Specificity | 2 | 2015 | 202 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2023 | 822 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2006 | 398 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2019 | 12262 | 0.060 |
Why?
|
| Ecosystem | 2 | 2018 | 76 | 0.060 |
Why?
|
| Skin Pigmentation | 1 | 2024 | 27 | 0.060 |
Why?
|
| Microcephaly | 2 | 2018 | 333 | 0.060 |
Why?
|
| Animals, Newborn | 1 | 2008 | 1007 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2017 | 690 | 0.060 |
Why?
|
| Comorbidity | 1 | 2009 | 1527 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2007 | 1252 | 0.060 |
Why?
|
| Acute Disease | 2 | 2018 | 1107 | 0.060 |
Why?
|
| Inflammation | 2 | 2023 | 1421 | 0.050 |
Why?
|
| Dominican Republic | 1 | 2023 | 16 | 0.050 |
Why?
|
| Tumor Necrosis Factors | 1 | 2023 | 12 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2420 | 0.050 |
Why?
|
| Paraquat | 1 | 2022 | 13 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2008 | 746 | 0.050 |
Why?
|
| Agrochemicals | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cations | 1 | 2022 | 39 | 0.050 |
Why?
|
| Chemokines | 1 | 2023 | 135 | 0.050 |
Why?
|
| Developing Countries | 1 | 2024 | 267 | 0.050 |
Why?
|
| Interleukins | 1 | 2023 | 120 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2022 | 44 | 0.050 |
Why?
|
| Cell Count | 1 | 2022 | 252 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2023 | 223 | 0.050 |
Why?
|
| Synteny | 1 | 2021 | 74 | 0.050 |
Why?
|
| Spatial Analysis | 1 | 2021 | 21 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 3146 | 0.040 |
Why?
|
| Hypertension | 1 | 2009 | 1316 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2017 | 972 | 0.040 |
Why?
|
| Injections, Intradermal | 1 | 2000 | 32 | 0.040 |
Why?
|
| Multigene Family | 1 | 2021 | 297 | 0.040 |
Why?
|
| Decision Trees | 1 | 2000 | 49 | 0.040 |
Why?
|
| Cerebral Ventriculitis | 1 | 2019 | 15 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 195 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 210 | 0.040 |
Why?
|
| HIV Seroprevalence | 1 | 2019 | 9 | 0.040 |
Why?
|
| Proteomics | 1 | 2022 | 496 | 0.040 |
Why?
|
| Raccoons | 1 | 2018 | 3 | 0.040 |
Why?
|
| Canidae | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cities | 1 | 2018 | 47 | 0.040 |
Why?
|
| Transcriptome | 2 | 2016 | 944 | 0.040 |
Why?
|
| Rodentia | 1 | 2018 | 45 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2000 | 97 | 0.040 |
Why?
|
| Communicable Diseases, Imported | 1 | 2018 | 6 | 0.040 |
Why?
|
| Guatemala | 1 | 2018 | 62 | 0.040 |
Why?
|
| Bites and Stings | 1 | 2018 | 29 | 0.040 |
Why?
|
| Chikungunya virus | 1 | 2018 | 27 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2022 | 817 | 0.040 |
Why?
|
| Geography, Medical | 1 | 2017 | 16 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 2517 | 0.040 |
Why?
|
| Arizona | 1 | 2017 | 21 | 0.040 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 2 | 1 | 2017 | 2 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2017 | 3 | 0.040 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2017 | 6 | 0.040 |
Why?
|
| DNA, Satellite | 1 | 2017 | 18 | 0.030 |
Why?
|
| Atrophy | 1 | 2017 | 229 | 0.030 |
Why?
|
| DNA, Intergenic | 1 | 2017 | 17 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2024 | 818 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 457 | 0.030 |
Why?
|
| HIV-1 | 1 | 2020 | 464 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 180 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 116 | 0.030 |
Why?
|
| Encephalitis, Arbovirus | 1 | 2016 | 2 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 100 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 1939 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 83 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2017 | 103 | 0.030 |
Why?
|
| Edema | 1 | 2017 | 135 | 0.030 |
Why?
|
| Cross Infection | 1 | 2019 | 323 | 0.030 |
Why?
|
| Coinfection | 1 | 2018 | 171 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2021 | 772 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 258 | 0.030 |
Why?
|
| Insect Control | 1 | 2016 | 13 | 0.030 |
Why?
|
| Onchocerciasis | 1 | 2016 | 20 | 0.030 |
Why?
|
| Filariasis | 1 | 2016 | 27 | 0.030 |
Why?
|
| Viral Load | 1 | 2018 | 384 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 91 | 0.030 |
Why?
|
| Fibrosis | 1 | 2017 | 428 | 0.030 |
Why?
|
| Leishmaniasis | 1 | 2016 | 33 | 0.030 |
Why?
|
| History, 19th Century | 1 | 2015 | 115 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 420 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 500 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2014 | 53 | 0.030 |
Why?
|
| Cuba | 1 | 2014 | 6 | 0.030 |
Why?
|
| Panama | 1 | 2014 | 12 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2014 | 36 | 0.030 |
Why?
|
| Antiprotozoal Agents | 1 | 2014 | 37 | 0.030 |
Why?
|
| Gestational Age | 1 | 2018 | 1160 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2014 | 90 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 159 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1236 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2015 | 274 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3543 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2000 | 1264 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 604 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 325 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 2137 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 1389 | 0.020 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2011 | 8 | 0.020 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2014 | 371 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2023 | 4498 | 0.020 |
Why?
|
| Strigiformes | 1 | 2010 | 1 | 0.020 |
Why?
|
| Salivary Glands | 1 | 2010 | 33 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2011 | 177 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2010 | 87 | 0.020 |
Why?
|
| Macaca | 1 | 2010 | 61 | 0.020 |
Why?
|
| Primates | 1 | 2010 | 79 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3030 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 859 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2011 | 219 | 0.020 |
Why?
|
| Immune System | 1 | 2010 | 90 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2010 | 167 | 0.020 |
Why?
|
| Biological Evolution | 1 | 2011 | 225 | 0.020 |
Why?
|
| Leukocytes | 1 | 2010 | 204 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 2035 | 0.020 |
Why?
|
| Echocardiography | 1 | 2014 | 1048 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 1696 | 0.020 |
Why?
|
| Climate | 1 | 2008 | 20 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 1697 | 0.020 |
Why?
|
| United Kingdom | 1 | 2008 | 190 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 2625 | 0.010 |
Why?
|